Targeted therapy for HER2 positive breast cancer by Jason A Incorvati et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Incorvati et al. Journal of Hematology & Oncology 2013, 6:38
http://www.jhoonline.org/content/6/1/38REVIEW Open AccessTargeted therapy for HER2 positive breast cancer
Jason A Incorvati1, Shilpan Shah1, Ying Mu2 and Janice Lu1,2*Abstract
Introduction: Breast cancer is the second most common cause of death for women behind lung cancer and the
most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue
to be enormously large numbers of disease incidence, deaths have been declining due to the disease with two
hallmark time frames. The first occurred during the mid to late 1980’s when hormonal therapy was introduced as a
treatment for ER/PR positive breast cancer. The second occurred in the late 1990’s when trastuzumab was
introduced in treating HER2 positive breast cancer. These remarkable accomplishments in developing novel
targeted therapies for breast cancer, along with a better understanding of the disease biology have improved
disease outcome over the past 20 years.
This article reviews the data presented at 2012 American Society of Clinical Oncology and 2012 San Antonio Breast
Cancer Symposium regarding progress made in the field of HER2 positive breast cancer and examines the future of
HER2 targeted therapy.
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The HER2 gene (ErbB2) is a member of a group of
epithelial tyrosine kinase receptors [1,2]. These receptors
also include HER1 (which is an EGFR receptor), HER3
(ErbB3), and HER4 (ErbB4) [2]. The HER2 protein tends
to dimerize with either HER1, HER3, or HER4 [2].
HER2 has no identified ligand, which allows it to al-
ways be in open confirmation to dimerize with HER1,
HER3, or HER4 [3]. Thus, when the HER2 gene is
amplified and overexpressed, it allows for cell growth,
survival, and cell differentiation through a signal trans-
duction cascade mediated by the activation of PI3K/Akt
and the Ras/Raf/MEK/MAPK pathways [4]. Before
HER2 directed therapies were created, having HER2
positive breast cancer meant hyperactivation of this
downstream pathway, which caused high recurrence
rates and increased mortality [4-8]. The development of
targeted HER2 therapies, has significantly improved the
outcome for patients with HER2 positive breast cancer.* Correspondence: janice.lu@stonybrookmedicine.edu
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Briefly, trastuzumab is a humanized monoclonal anti-
body directed against the extracellular domain of the
HER2 receptor which prevents ligand-independent
HER2 signaling. It was initially approved by the FDA for
metastatic breast cancer in 1998 [9].
The optimal duration of adjuvant trastuzumab therapy
remains an important issue. HERA (BIG 01–01) trial was
presented at 2012 San Antonio Breast Cancer Symposium
and published by Goldhirsch et al. [10]. The trial was a
phase III randomized trial involving 5102 women with
HER2 positive early breast cancer to trastuzumab (T) every
3 weeks for 1 yr, trastuzumab (T) for 2 years, or observa-
tion [10]. The unadjusted hazard ratio (HR) for an event in
the 2-yr vs. 1-yr (T) arms was 0.99 (95% CI 0.85–1.14; p =
0.86) [10]. Overall survival (OS) in the two arms was com-
parable [HR = 1.05 (95% CI 0.86–1.28; p = 0.63)] [10]. The
primary cardiac endpoint (symptomatic congestive heart
failure) was comparable (1.0% vs. 0.8% for 2-yr and 1-yr
arms), but the secondary cardiac endpoint (asymptomatic
cardiac dysfunction) was higher in the 2-yr arm (7.2% vs.
4.1%) illustrating that at this time the standard of care of 1
year of trastuzumab therapy should remain because of the
increased cardio-toxic events of longer trastuzumab ther-
apy along with the lack of support for any additional
patient benefit in the 2-yr treatment arm [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Incorvati et al. Journal of Hematology & Oncology 2013, 6:38 Page 2 of 9
http://www.jhoonline.org/content/6/1/38By contrast, the PHARE trial was designed to evaluate
the advantages of shorter duration of adjuvant trastuzumab
therapy. The data was supported by the results of the
FINHER trial using trastuzumab for a shorter duration.
The FINHER trial showed that 9 weeks of trastuzumab (T)
therapy provided a similar magnitude of benefit than the
standard of care 1-year treatment [11]. Thus, the French
National Cancer Institute (INCa) initiated a randomized
non-inferiority trial aiming to compare a shorter (T) ex-
posure of 6 months versus the standard 12 months. 3382
patients were randomized to 6 or 12 months of (T). Unfor-
tunately, the results were inconclusive regarding the non-
inferiority (p = 0.14) [11].
Information about a newer trial, presented at the San
Antonio Breast Conference, is the phase III randomized,
controlled PERSEPHONE study. This trial, like the
PHARE study, is comparing six months of trastuzumab
to the standard 12 month duration in patients with
HER2 positive early breast cancer in respect of disease
free survival, safety and cost-effectiveness [12]. The goal
for this trial is to evaluate patients with early stage
HER2 positive breast cancer in a total of 4000 patients
divided into each of the two treatment groups [12]. This
trial will provide direction on the optimal duration of
trastuzumab adjuvant treatment for HER2 positive early
stage breast cancer.
Lastly, Romond et al. presented the final joint analysis
of overall survival from the NCCTG N9831 and NSABP
(B31). This study was based on a 2 arm trial of 2,028
women receiving doxorubicin/cyclophosphamide followed
by paclitaxel compared to 2018 women receiving doxo-
rubicin/cyclophosphamide followed by paclitaxel plus
trastuzumab [13]. At 10 years, the disease-free survival
was 73.7% with doxorubicin/cyclophosphamide followed
by paclitaxel plus trastuzumab vs 62.2% with doxorubicin/
cyclophosphamide followed by paclitaxel for an absolute
improvement of 11.5% and 40% risk reduction (p <
0.0001) mostly related to the higher distant recurrences
that occurred in the non-trastuzumab arm [13]. Similarly,
the overall survival at 10 years was 84% vs 75.2% for an
absolute improvement of 8.8% and 37% risk reduction
(p < 0.0001) [13].
Lapatinib
Lapatinib is a dual EGFR/ErbB2 reversible tyrosine kin-
ase inhibitor (blocking both HER1 & HER2); thereby
suppressing downstream pathways of MAPK/Erk1/2 and
PI3K/Akt pathways [14]. This was the second HER2
targeted agent approved based on the study published by
Geyer et al., which demonstrated that lapatinib plus
capecitabine was superior to capecitabine alone in
women with HER2 positive advanced breast cancer that
has progressed after treatment with regimens that in-
cluded trastuzumab and chemotherapy agents [15].At ASCO 2012, the NSABP (B-41) protocol was
presented by Robidoux et al. It is a randomized phase III
trial of neoadjuvant therapy (anthracycline plus cyclophos-
phamide (AC) followed by weekly paclitaxel (WP) for pa-
tients with palpable and operable HER2 positive breast
cancer comparing the combination of trastuzumab (T)
plus lapatinib (L) to trastuzumab and to lapatinib adminis-
tered with weekly paclitaxel following (AC) [16]. There
were 529 patients randomized in the trial. The pathologic
complete response (pCR) was 52.5% for AC +WP+T,
53.2% (p = 0.9 T vs L) for AC +WP+ L, and 62% (p =
0.095 T vs T + L) for AC +WP+TL [16]. pCR percentages
in the hormone receptor positive (HR+) subset were
46.7%, 48% (p = 0.85 T vs L), and 55.6% (p = 0.18 T vs T +
L), respectively, and were 65.5%, 60.6% (p = 0.57 T vs L),
and 73% (p = 0.37 T vs T + L) in the hormone receptor
negative (HR-) cohort [16]. The corresponding pCR breast
and nodes percentages were 49.1%, 47.4% (p = 0.74), and
60.4% (p = 0.04) [16]. It was concluded that substitution of
lapatinib for trastuzumab in combination with the chemo-
therapy program employed in this study resulted in similar
high percentages of pCR in both HR + and HR- cohorts
[16]. Combined HER2 targeted therapy produced a nu-
merically higher pCR percentage than single agent HER2
directed therapy, but the difference was not statistically
significant [16].
Currently, Takano et al. is evaluating a randomized
phase II trial (ELTOP) in patients with HER2 positive
metastatic breast cancer (MBC) previously treated with
trastuzumab and taxanes comparing capecitabine 2,500
mg/m2/day on days 1 to 14 plus trastuzumab (8 mg/kg
loading dose and 6 mg/kg thereafter) on day 1 every 3
weeks (HX) and capecitabine 2,000 mg/m2/day on days
1 to 14 plus lapatinib 1250 mg/day on days 1 to 21 every
3 weeks (LX) [17]. The study’s primary endpoint is
progression-free survival with secondary endpoints in
overall response rate, overall survival, proportion of pa-
tients progressing brain metastases as site of first pro-
gression, and safety [17]. The study is also investigating
biomarkers related to the HER family [17].
Other clinical data presented from the 2012 San
Antonio Breast Symposium was from a phase I/II trial of
primary chemotherapy with non-pegylated liposomal
doxorubicin, paclitaxel and lapatinib in patients with
HER2 positive early stage breast cancer (P1-14-05) [18].
A total of 84 patients were included in the trial [18]. Pre-
liminary data reveals the combination of non-pegylated
liposomal doxorubicin, paclitaxel and lapatinib is well
tolerated with no worsening cardiac toxicity and has
high antitumor activity in patients with HER2 positive
primary breast cancer [18].
A subsequent study by Kodack et al. (P3-12-03), is
looking at combined targeted therapy with HER2 and
VEGFR2 for effective treatment of HER2 amplified
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tastases do not respond well to HER2 inhibitors and are
often the reason for treatment failure [19]. Pre-clinical
data with an HER2 amplified mouse model of brain
metastasis using an orthotopic xenograft of BT474 cells
in mice, has revealed that the combination of either
trastuzumab and DC101 (anti-VEGFR2 inhibitor) or
lapatinib and DC101 significantly slowed metastatic
tumor growth in the brain with marked necrosis of brain
lesions. This resulted in a striking improvement in over-
all survival in mice [19]. Thus, a new clinical trial is now
recruiting patients to evaluate the efficacy of bevacizumab
in breast cancer patients with active brain metastases, in-
cluding its combination with trastuzumab in patients with
HER2 positive disease [19].
The MA.31 trial was also presented at ASCO 2012.
This trial tested the relative efficacy of lapatinib (L) vs
trastuzumab (T) in first line metastatic breast cancer.
The study accrued 652 patients. The regimen of arm 1
was (L) dose of 1250 mg with Tax followed by 1500 mg
(L) daily (LTax/L) compared to arm 2 of (T) 2 mg/kg
weekly or 6 mg/kg every 3 weeks plus Tax followed by
(T) 6 mg/kg every 3 weeks (TTax/T) [20]. The progres-
sion free survival was inferior with (LTax/L) of 8.8
months compared to (TTax/T) of 11.4 months [20].
There was no difference in overall survival between the
2 arms [20]. Thus, it appears that lapatinib is associated
with a shorter progression free survival as a first line
treatment in metastatic breast cancer patients compared
to trastuzumab.
The San Antonio Breast Conference provided one
more report on Lapatinib investigative trials, Estevez
et al. (P5-18-15) investigated lapatinib in HER2 positive
ductal carcinoma in situ (DCIS) [21]. The study was
aimed at determining the effects of Ras/Raf/MAK and
PI3K/AKT signaling pathway of the HER2 inhibitor
lapatinib in patients with HER2 positive DCIS, as well as
the correlation with radiological and pathological re-
sponses [21]. A total of 20 patients with HER2 positive
DCIS received a dose of 1500 mg daily of lapatinib for 4
consecutive weeks prior to surgical resection with radio-
graphic changes evaluated by MRI [21]. The results re-
vealed that lapatinib modulated HER2 signaling in 11
patients by decreasing cytoplasm pERK in 11/20 patients
and 7/20 presented with decrease in MRI signaling and
tumor size [21]. Thus, Esteves concluded that 4 weeks of
pre-surgical lapatinib in DCIS revealed significant anti-
proliferative effects [21].
Synergy with lapatinib and trastuzumab
With newer HER2 drugs in the pipeline, researchers in-
vestigated the effects of using lapatinib and trastuzumab
together. It has been found that lapatinib could enhance
trastuzumab by increasing the apoptotic effect [4].Blackwell et al. presented results of the Phase III
EGF104900 trial, which demonstrated that lapatinib plus
trastuzumab significantly improved progression-free sur-
vival (PFS) and clinical benefit rate versus lapatinib
monotherapy [22]. A total of 291 randomly assigned
HER2 positive metastatic breast cancer patients whose
disease that progress during prior trastuzumab therapy
were assigned to receive lapatinib monotherapy or a
combination of lapatinib and trastuzumab [22]. The
study concluded that absolute overall survival (OS) rates
were 10% at 6 months and 15% at 12 months in the
combination arm (lapatinib/trastuzumab) compared with
the monotherapy (lapatinib) arm demonstrating a sig-
nificant 4.5-month median OS advantage with lapatinib
and trastuzumab combination in support dual HER2
blockade in patients previously treated HER2 positive
metastatic breast cancer [22].
At the San Antonio Breast Conference 2012, Johnson
et al. presented the ALTERNATIVE Study, which is a
phase III, randomized, open-label, multicenter trial exam-
ining the efficacy of lapatinib/trastuzumab/aromatase in-
hibitor versus trastuzumab/aromatase inhibitor [23]. The
theory regarding this trial is the fact that HER2 positive
patients is associated with a poor prognosis and hormone
resistance to endocrine therapy in patients that are hor-
mone receptor positive; thus, this trial wants to evaluate
how dual anti-tyrosine kinase inhibitor with an aromatase
inhibitor compares to single agent tyrosine kinase with an
aromatase inhibitor in overall survival. The target date for
initial results is in 2016 [23].
Crown et al. also presented an ongoing phase III study
evaluating dual anti tyrosine kinase, however, this study
is looking at hormone receptor negative breast cancer
with the combination of paclitaxel in the first line treat-
ment of metastatic breast cancer [24]. This study will
not only evaluate for efficacy but also predictive bio-
markers of response to trastuzumab and or lapatinib
[24]. In similar fashion, Lin et al. is evaluating whether
the combination of trastuzumab and lapatinib in meta-
static breast cancer undergoing maintenance therapy as
well improves progression free survival [25].
Newer HER2 drug therapies
In addition to HER2, HER1 and particularly HER3, play
an important role in forming heterodimers with HER2
allowing for critical activation of the PI3K/Akt pathway
driving the pathways of angiogenesis, cell survival, mi-
gration, apoptosis, and cell proliferation [26]. The drug
therapies are summarized in Table 1.
Pertuzumab
Pertuzumab is a monoclonal antibody which attempts to
block the heterodimerization of HER2 with HER3 by
interfering with the ligand-dependent HER3 mediated
Table 1 Summary of drug therapies
Target Agent Most common adverse events
reported to FDA




Pertuzumab Diarrhea, alopecia, neutropenia,



















Pazopanib Diarrhea, change in hair color,








Afatinib Safety and efficacy not fully
established by the FDA.
NCT00826267 Boehringer Ingelheim
Likely gastrointestinal and skin-










Neratinib Safety and efficacy not fully
established by the FDA.




Incorvati et al. Journal of Hematology & Oncology 2013, 6:38 Page 4 of 9
http://www.jhoonline.org/content/6/1/38signaling [26]. This drug has only shown modest anti-
tumor clinical activity alone; however, it appears to be a
very good synergistic drug combined with trastuzumab.
The NEOSPHERE, neoadjuvant trial, took patients with
operable HER2 positive breast cancer (n = 417) and placed
them in four arms receiving 4 cycles: docetaxel plus
trastuzumab and pertuzumab, docetaxel plus trastuzumab,
docetaxel plus pertuzumab, or pertuzumab plus tras-
tuzumab without chemotherapy [27]. The pathologic
complete response rates were 45.8% for the combined
regimen of docetaxel plus trastuzumab + pertuzumab,
29% in docetaxel plus trastuzumab (P = 0.014), 24% in
docetaxel plus pertuzumab (P = 0.003), and 16.8% in the
trastuzumab + pertuzumab without chemotherapy [27].
This study led to the CLEOPATRA study, which takes
HER2 positive metastatic breast cancer patients ran-
domized to pertuzumab + trastuzumab and docetaxel or
placebo + trastuzumab and docetaxel [28]. In the CLEO-
PATRA study, 808 patients with HER2 positive metastaticbreast cancer were randomly assigned with the primary
end point being progression-free survival [28]. The me-
dian progression-free survival was 18.5 months in the
pertuzumab group compared to 12.4 months in the
control group, which led to the FDA approval of
Pertuzumab [28]. In the intention-to-treat population,
267 patients died by data cutoff (May 14, 2012), 154
(38%) of 406 in the placebo group and 113 (28%) of 402
in the pertuzumab group [29]. Median overall survival
was 37.6 months (95% CI 34.3—NE [not estimable]) in
the placebo group but had not been reached (95% CI
42.4—NE) in the pertuzumab group (hazard ratio 0.66,
95% CI 0.52-0.84; p = 0.0008) [29].
Pertuzumab is being evaluated in a phase III study
(ClinicalTrials.gov identifier: NCT01358877 “APHINITY”)
as an adjuvant therapy in order to investigate the optimal
regimen for HER2 positive breast cancer with the primary
outcome being disease free survival [30]. Patients will
be randomized (1:1) prior to any chemotherapy to one
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chemotherapy for 3–4 cycles followed by taxane × 3–4
cycles with trastuzumab with or without pertuzumab
(for a total of 52 weeks). Another approach is to give
non-anthracycline-based chemotherapy (docetaxel +
carboplatin) × 3–4 cycles followed by trastuzumab with
or without pertuzumab for 52 weeks [30].
A phase II study, VELVET trial, by Perez et al. is an
ongoing trial evaluating combination of pertuzumab,
trastuzumab and vinorelbine for first-line treatment in
patients with HER2-positive locally-advanced or meta-
static breast cancer to assess response rate and safety is
also ongoing [31]. This trial will provide input regarding
the use of pertuzumab and trastuzumab with chemo-
therapy besides taxane.
Another ongoing phase II study, PERTAIN trial, by
Rimawi et al. is comparing trastuzumab and a aromatase
inhibitor with or without pertuzumab as first-line
therapy in hormone-positive, HER2 positive metastatic
breast cancer in postmenopausal women [32]. Patients
can receive induction chemotherapy (taxane) as per in-
vestigator’s discretion. This trial will provide insight into
the benefits of single or dual HER2 targeted therapies in
combination with aromatase inhibitor.
At the 2012 San Antonio Breast Conference, Baselga
and colleagues presented an analysis which explored the
predictive and/or prognostic value of biomarkers in tis-
sue samples and serum in the CLEOPATRA study popu-
lation [33]. These markers included HER1, HER2, HER3,
PTEN, pAKT, AREG, c-myc, betacellulin etc. detected
by methods such as immunohistochemistry, reverse tran-
scription polymerase chain reaction, ELISA and fluores-
cence in situ hybridization [33]. The results suggested that
HER2 remains the only marker suitable for use when
selecting patients for anti-HER2 therapy. There was an in-
dication that the presence of the PI3K mutation would
suggest a poorer prognosis within the HER2 positive
population, and that perhaps adding a PI3K pathway-
targeted agent would improve outcomes [33].
Another subgroup analysis by Miles and colleagues
evaluated the effect of age in the CLEOPATRA study
comparing the safety and efficacy in elderly patients
[34]. The conclusion from the adverse effect (AE) profile
was that age should not restrict the use of Pertuzumab.
Two ongoing trials were presented at the San Antonio
Breast Symposium, which looked at pertuzumab. The
first was a single arm phase IIIb study of pertuzumab
and trastuzumab with a taxane as first-line therapy for
patients with HER2 positive advanced breast cancer
(PERUSE) [35]. PERUSE will evaluate patients with
HER2 positive metastatic or locally recurrent breast
cancer who have not received systemic therapy for meta-
static cancer to assess the safety and tolerability of
trastuzumab + pertuzumab with a choice of taxane asfirst-line therapy [35]. The second was a prospective,
phase II study evaluating the therapeutic value of liposo-
mal anthracyclines in HER2 positive breast cancer with
dual anti-HER2 therapy (trastuzumab + pertuzumab) in
evaluating cardiac safety given the possibility of increased
cardiotoxicity with anthracyclines and trastuzumab [36].
Ttrastuzumab-maytansine [dm1]
Trastuzumab-maytansine [DM1] is an immunoconjugate
agent combining trastuzumab with an antimicrotubule
cytotoxic chemotherapeutic agent linked together by a
covalent bond [26]. In Phase I and Phase II studies the
drug has been found to be well-tolerated with signifi-
cant objective response rates and improvements of
progression-free survival.
Hurvitz et al. presented phase II data at ESMO 2011
and the data was subsequently published in 2013 [37].
The study showed that the patients treated with
trastuzumab emtansine (T-DM1) achieved roughly a
40% reduction in risk of disease progression compared
with those on a standard combination of trastuzumab
plus docetaxel (14.2 months versus 9.2 months), (HR
0.59, P = 0.035) [37]. A total of 137 patients with locally
advanced or metastatic HER2 positive breast cancer
naive to chemotherapy or targeted therapy were exam-
ined with a primary endpoint of progression-free sur-
vival [37]. Overall, the toxicity was far lower among
those on the investigational agent (46.4% versus 89.4%)
and more women on standard care discontinued therapy
due to side effects (28.8% versus 7.2%) [37]. Thus, it was
concluded that first-line treatment with T-DM1 for pa-
tients with HER2 positive metastatic breast cancer pro-
vided a significant improvement in PFS, with a favorable
safety profile, compared to standard combination ther-
apy of trastuzumab plus docetaxel.
EMILIA is a T-DM1 registration trial comparing
trastuzumab-DM1 versus lapatinib plus capecitabine,
which led to FDA approval of this drug in February of
2013 [38]. The primary results from this phase III study
presented by Blackwell et al., in HER2 positive locally-
advanced or metastatic breast cancer patients previously
treated with trastuzumab and taxane examined 978 pa-
tients with the primary endpoint being PFS, OS and
safety [38]. Blackwell reported that there was a signifi-
cant improvement in median progression-free survival
9.6 months in the T-DM1 arm compared with 6.4
months in the capecitabine/ lapatinib arm (stratified
hazard ratio [HR] = 0.650, p < 0.0001) and safety and sec-
ondary efficacy endpoints favored T-DM1 [38]. These
result led to the approval of T-DM1 in February of 2013.
The final overall survival analysis will be fully presented
in 2014; however, preliminary data reveals that there is a
trend for improvement in overall survival 84.1% with T-
DM1 compared to 77% with capecitabine/lapatinib at 1
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lapatinib at 2 years [38].
The MARIANNE trial is a phase III 3-arm study evalu-
ating TDM-1, TDM-1 plus pertuzumab or trastuzumab
plus a taxane as first line metastatic regimen [39]. The re-
sult will provide insight regarding which regimen is the
winner for first line metastatic breast cancer.
At the San Antonio Breast Conference, Wang et al.
presented an evaluation of the pharmacokinetics and
exposure-efficacy relationship of T-DM1 in the EMILIA
phase III study. Wang concluded that T-DM1 pharma-
cokinetics data were similar in previous phase II studies
with historical data of single agent T-DM1 [40]. Further-
more, there was no significant exposure-efficacy rela-
tionship observed between T-DM1 AUC (P = 0.23 for
PFS and P = 0.53 for OS) or DM1 Coax (P = 0.96 for PFS
and P = 0.34 for OS) and PFS or OS, respectively [40].
Pazopanib
Pazopanib is a selective multi-targeted receptor tyrosine
kinase inhibitor of VEGF receptors 1, 2, 3, PDGF recep-
tor a/β, and cytokine receptor c-kit that blocks tumor
growth and inhibits angiogenesis. At ASCO 2012, a
phase II study comparing lapatinib (1500 mg) plus pla-
cebo and lapatinib (1500 mg) with pazopanib (800 mg)
in patients with relapsed HER2 positive inflammatory
breast cancer (IBC) was presented by Cristofanilli et al.
[41]. 76 patients were examined in a 1:1 double blind
study until disease progression, unacceptable toxicity, or
death occurred. Due to significantly increased incidence
of grades 3 and 4 diarrhea at this dose (71% in the com-
bination arm versus 24% in lapatinib arm) this cohort
was closed [41]. Thus, the protocol was amended such
that an additional 88 patients were randomized in a
5:5:2 ratio to receive daily monotherapy lapatinib 1,500
mg, lapatinib 1,000 mg + pazopanib 400 mg, or mono-
therapy pazopanib 800 mg with a primary endpoint of
obtaining an overall response rate (ORR) [41]. In this
amended cohort, the ORR for patients treated with
lapatinib (n = 36) was 47%, lapatinib + pazopanib (n = 38)
was 58%, and pazopanib (n = 13) was 31%. However, the
median PFS was not increased compared to lapatinib
alone [41]. The combination also had increased toxicity
resulting in more dose reductions, modifications, and
treatment delays [41]. It was concluded that there was
no clinical benefit of the combination as opposed to sin-
gle agent lapatinib [41]. In fact, there was increased inci-
dence of toxicities with the combination especially at
higher dose of pazopanib.
Afatinib
Afatinib is an irreversible binder of the HER receptors
[HER1, HER2, and HER3] [26]. The drug appears to
have anti-tumor activity by itself or with chemotherapyin patients with progressive HER2 positive breast cancer.
As presented at ASCO 2012, a small phase II trial
studying single-agents afatinib (50 mg daily), lapatinib
(1500 mg daily) and trastuzumab (2 mg/kg weekly after
loading dose) as neoadjuvant monotherapy in locally-
advanced (stage III and inflammatory BC) for 6 weeks
pre-operatively suggested that afatinib had higher object-
ive response rate compared to the other 2 agents (80%
vs. 75% vs. 36% respectively) [42]. It was concluded that
further studies are needed to identify the potential role
of afatinib as a single-agent or in combination in HER2
positive breast cancer patients.
To assist in addressing this issue, there is an ongoing
phase III study of patients, previously treated with
trastuzumab, which is evaluating vinorelbine plus afatinib
versus vinorelbine plus trastuzumab [43]. The Phase III,
open-label randomized study began enrolling in June 2010
with a recruitment target of 780 patients and a primary
end-point being PFS [44]. The patients will be random-
ized in a 2:1 fashion between Afatinib + Vinorelbine and
Trastuzumab + Vinorelbine arms [44]. The dose of
afatinib is 40 mg PO daily, vinorelbine is 25 mg/m2/wk
and trastuzumab is 2 mg/kg/week after initial loading
dose of 4 mg/kg. Patients will receive continuous treat-
ment until disease progression or toxicity [44].
Besides this phase III trial, there are three other phase
II studies that were presented.
Firstly, Hickish et al. presented a phase II study (LUX-
breast 2) evaluating the objective response of afatinib at
dose of 40 mg/day in metastatic breast cancer patients
who progressed on prior trastuzumab or lapatinib as
single-agent followed by afatinib ‘beyond progression’
with chemotherapy (weekly Paclitaxel 80 mg/m2 or
Vinorelbine 25 mg/m2) [45]. 120 patients who do not
have rapidly progressing visceral disease or active brain
metastasis will be evaluated [45]. Enrollment began in
May 2011 at about 35 sites in 5 countries with a primary
endpoint being objective response [45].
Secondly, LUX-breast 3 trial presented by Joensuu et al.
is an ongoing phase II study, which randomizes HER2
positive breast cancer patients with progressive brain me-
tastases (after trastuzumab or lapatinib based therapy) to
single-agent afatinib versus afatinib + vinorelbine versus
the investigator’s choice of approved therapy [46]. The
study began in Oct 2011 and is still enrolling. The primary
end-point is benefit at 12 weeks (absence of CNS/ extra-
CNS disease progression and no tumor-related neuro-
logical worsening with any increase in steroid dose) [46].
Lastly, Swanton et al. presented a phase II trial
evaluating the efficacy and safety of afatinib in inflam-
matory breast cancer [47]. This study takes into account
the fact that inflammatory breast cancer commonly lacks
ER/PR and more frequently harbors HER2 gene amplifi-
cation (~40%), and EGFR overexpression (~30%), which
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with HER2 expressing inflammatory breast cancer will
be given afatinib (that binds to HER1 & HER2) with or
without vinorelbine. Both trastuzumab naïve and failed
patients are being enrolled since Aug 2011 with a pri-
mary end-point of Clinical Benefit Rate (CR, PR or SD)
for greater than 6 months [47].
Neratinib
Neratinib, which is similar to Afatinib, is another irre-
versible binder of the HER receptors [HER1, HER2, and
HER3] [26]. This drug has been looked at in studies with
patients that are HER2 positive and have been exposed
to prior trastuzumab treatment or never have received
any anti-HER2 treatment in the past. In phase II studies,
neratinib has been shown to be well-tolerated and
shown significant clinical activity [48]. A phase II study
looking at 136 HER2 positive patients showed a 24%
response rate in women previously treated with
trastuzumab with a progression-free survival at 16 weeks
of 59%, and a 56% response rate in patients who have
never received any anti-HER2 treatment prior with a
progression-free survival of 78% at 16 weeks [49]. It has
also been shown to be more potent and have a more
prolonged inhibitory effect as compared to lapatinib and
can bypass potential resistance pathways [49]. These
positive results have led to several phase III studies with
neratinib. For example, the EXTENET trial is a random-
ized, double-blind, placebo-controlled trial of neratinib
after trastuzumab in women with early-stage HER2
overexpressed/amplified breast cancer [50]. The purpose
of this study is to investigate whether neratinib can
further reduce the risk of recurrence from previously di-
agnosed HER-2 positive breast cancer after adjuvant
treatment with trastuzumab, and evaluate for disease-
free survival as the primary endpoint with results
expected by 2017 [50]. At ASCO 2012, Canonici et al.
presented effect of neratinib alone and in combination
with trastuzumab in HER2 positive breast cancer cell
lines [51]. The results indicate that in HER2 positive cell
lines, including trastuzumab and/or lapatinib resistant
cells, are sensitive to neratinib alone with IC50 values
(concentration which inhibits 50% of growth). This study
showed significant benefit with neratinib as a single
agent and in combination with trastuzumab in both
trastuzumab sensitive and lapatinib resistant cell lines
[51]. It was concluded that neratinib should be studied
further in HER2 positive breast cancer patients, includ-
ing trastuzumab and lapatinib resistant cases.
A phase I NSABP study (FB-8) by Jankowitz et al. eval-
uated weekly paclitaxel with neratinib and trastuzumab
in women with metastatic HER2 positive breast cancer.
It showed good tolerability and activity in patients pre-
treated with anti-HER2 therapy and chemotherapy [52].This study provided recommendations for doses of the
neratinib and trastuzumab combination for phase II
NSABP FB-7 trials, with the purpose of determining the
activity and safety profile of Neratinib as a mono-blockade
or in combination with Trastuzumab as dual blockade in
neoadjuvant therapy of locally advanced breast cancer
(stage IIB, III A, B and C) followed by postoperative
trastuzumab for one year [52]. A total of 126 patients will
be enrolled in the study with a primary goal of determin-
ing the pathologic complete response in breast and axil-
lary lymph nodes following completion of neoadjuvant
therapy. The efficacy of neratinib as a multi inhibitor of
the HER family has yet to be fully proven [52].
The results of an interesting trial [TBCRC 022]
presented at the San Antonio Breast Conference looked
at Neratinib in CNS disease. Pre-clinical data suggests it
may cross the blood brain barrier [53]. This phase II,
multicenter, open-label study will evaluate patients with
HER2+ breast cancer and brain metastases with a pri-
mary endpoint of CNS objective response rate (ORR)
and additional endpoints including non-CNS ORR,
progression-free survival, overall survival (OS), site of
1st progression, and toxicity [53]. This trial may assist
in providing more drugs in the arsenal to fight CNS
positive HER2 breast cancer.
Conclusion
In this article, we reviewed studies presented at 2012
American Society of Clinical Oncology and 2012 San
Antonio Breast Cancer Symposium on the development
of HER2 positive breast cancer treatments. Although
great strides have been made in the treatment of breast
cancer and in particular, HER2 positive breast cancer,
the disease has not been conquered. There are diverse
potential mechanisms that make the currently FDA ap-
proved HER2 targeted agents, trastuzumab, lapatinib,
pertuzumab, and T-DM1 to be refractory. One of the
many challenges we struggle with are the multiple path-
ways of resistance involved. We seek to discover ways in
which the combination therapy may assist in blocking
these pathways. Many new agents, some discussed in
this paper, present new and exciting strategies to combat
HER2 positive breast cancer, which provide additional
safe and effective treatment options, either as single
agents or in combination regimens. Equally as import-
ant, further investigation is ongoing in evaluating bio-
logical markers to assist in tailoring treatments to the
individual and not just to the disease. Identification of
potential biomarkers would provide the clinician valu-
able information with regard to response and clinical
benefit [54-56]. Many of the clinical trials that are cur-
rently ongoing collect tissue and blood samples and
probe for potential biologic markers related to cell pro-
liferation, cell cycles, angiogenesis, or signal transduction
Incorvati et al. Journal of Hematology & Oncology 2013, 6:38 Page 8 of 9
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understand the mechanism of resistance and provide
cure for HER2 positive breast cancer.
In order to better understand HER2 positive breast
cancer, we need further dynamic and innovative clinical
trial designs in the form of basic, translational, and
clinical research to improve patient outcomes in drug
targeted HER2 positive breast cancer. For example, T-
DM1 was recently approved by the FDA as second line
metastatic therapy. Can T-DM1 be given as a first line
agent given its efficacy and low toxicity profile? What
about evaluating dual anti-HER2 therapy, such as T-
DM1 plus pertuzumab as opposed to T-DM1 alone in
the neoadjuvant and adjuvant settings? How effectively
does neratinib overcome resistance with combination
therapy with, for instance, trastuzumab, pertuzumab or
T-DM1? Such pertinent questions are being evaluated
by ongoing and future trials and need to be addressed,
along with many others by researchers.
We foresee that in the future, HER2 breast cancer will
no longer be lumped as a single entity in breast cancer,
but a multiple different subsets within a single entity of
HER2 breast cancer. The ultimate purpose is to be able
to customize drug therapy based on a variety of clinical
and translational research, and to optimize drug treat-
ment for HER2 positive breast cancer.
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